300436.SZFujian Cosunter Pharmaceutical Co., Ltd.
Nov 12, 2026 — NRDL & VBP Pricing Updates
Chart by TradingViewThe schedule
- Thu12Nov
Annual updates on China's Volume-Based Procurement (VBP) and National Reimbursement Drug List (NRDL) inclusions, threatening to compress the company's specialty generic pricing.
- Thu14Jan
Market reassessment of foreign capital flows into Chinese biopharma amid evolving trade policies under President Trump.
- Fri23Apr
Full-year 2026 earnings print. Focus will shift purely to the company's cash runway and the rising probability of a highly dilutive capital raise.
Past
- Fri28Aug
Actual outcome: Bear · $86.58 at outcome
Price reached or fell below bear floor ($76.00) at outcome date.
Fujian Cosunter reports 1H 2026 results. The street will scrutinize operating margins and pipeline viability given the extreme 35.7x P/S multiple and ongoing cash burn.